Siemens Healthineers has debuted its second pathway for its AI-Pathway Companion. This new pathway is focused on non-small cell lung cancer, supporting personalized and standardized decision-making along the whole treatment process.
The AI-Pathway Companion Lung Cancer assists multidisciplinary teams (MDT) by facilitating patient management and case reviews in a single dashboard, providing quality checks on data completeness and enabling the documentation of clinically relevant patient-specific notations.
“During lung MDT discussion, it frequently becomes apparent that a key diagnostic report or other crucial information is not yet available,” said Mathias Prokop, head of the department of radiology, nuclear medicine and anatomy at Radboud University Nijmegen.
“These patients have to be discussed again in the next meeting. This wastes time and effort for all physicians involved in the MDT. A digital assistant, which ensures that…